Obsidian Therapeutics, Inc.
No SEC Form 4 filings for $OBX in the last 30 days.
See all $OBX insider activity →Obsidian Therapeutics (OBX) shares rose 16.36% to $32.00 after the company enrolled the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study for amsoki-cel (OBX-115) in checkpoint inhibitor-resistant advanced melanoma. Obsidian also completed a $350 million private placement, expecting cash to fund operations into 2H 2028.
24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.
Analyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.
Over the past 7 days, alphai's AI scored 5 news stories mentioning OBX (Obsidian Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent OBX coverage spans financial news, technology and mergers & acquisitions.
Enrollment progress plus prior response-rate results and a large cash raise support a near-term momentum bid, while pushing key readout risk into 2027.
Buy initiation can still shift sentiment, but lack of target reduces precision.
Positive initiation can boost sentiment for biotech risk-on positioning.
Reverse-merger listing plus fresh capital is a near-term liquidity and valuation catalyst for OBX, with funding runway into 2H 2028.
This filing is a primary-source update that can change near-term valuation assumptions, but the provided text is mostly lease boilerplate and does not include financial figures.
alphai scores every news story that mentions OBX with an AI model for sentiment and relevance, and aggregates insider trades from Obsidian Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Obsidian Therapeutics (OBX) shares rose 16.36% to $32.00 after the company enrolled the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study for amsoki-cel (OBX-115) in checkpoint inhibitor-resistant advanced melanoma. Obsidian also completed a $350 million private placement, expecting cash to fund operations into 2H 2028.
3 min read24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.
4 min readAnalyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.
7 min readRTW Biotech Opportunities said Obsidian Therapeutics completed its merger with Galera Therapeutics Inc. via a reverse merger, with a concurrent private financing of about $350m. The combined company began trading on Nasdaq as Obsidian Therapeutics under ticker OBX on 4 Aug 2026. Proceeds are expected to fund operations into H2 2028.
3 min readObsidian Therapeutics, Inc. (OBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.14 18 d309963dex1014.htm EX-10.14 EX-10.14 Exhibit 10.14 Execution Copy LEASE 1030 MASSACHUSETTS AVENUE CAMBRIDGE, MASSACHUSETTS CAMBRIDGE 1030 MASS AVE, LLC a Delaware limited liability company as Landlord, and OBSIDIAN THERAPEUTICS, INC. a Delaware corporation as Tenant.
6 min read
